Biomarkers in osteoarthritis: current status and outlook — the FNIH Biomarkers Consortium PROGRESS OA study

Currently, no disease-modifying therapies are approved for osteoarthritis (OA) use. One obstacle to trial success in this field has been our existing endpoints’ limited validity and responsiveness. To overcome this impasse, the Foundation for the NIH OA Biomarkers Consortium is focused on investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunter, David J., Collins, Jamie E., Deveza, Leticia, Hoffmann, Steven C., Kraus, Virginia B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509067/
https://www.ncbi.nlm.nih.gov/pubmed/36692532
http://dx.doi.org/10.1007/s00256-023-04284-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509067/
https://www.ncbi.nlm.nih.gov/pubmed/36692532
http://dx.doi.org/10.1007/s00256-023-04284-w

Ejemplares similares